Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 2/2003

01-03-2003 | Case Report

Severe livedo vasculitis treated with potassium iodide

Authors: Zeev Abraham, Michael Rozenbaum, Elena Portnoy, Itzhak Rosner

Published in: Rheumatology International | Issue 2/2003

Login to get access

Abstract

A young woman presenting severe livedo vasculitis (LV) was successfully treated with potassium iodide (KI). Previous attempts to cure her disorder with corticosteroids, low-dose aspirin, and azathioprine in various combinations had failed. To our knowledge, this is the first report of LV treated with KI.
Literature
1.
Sterling JB, Heymann WR (2000) Potassium iodide in dermatology: a 19th century drug for the 21st century. Uses, pharmacology, adverse effects, and contraindications. J Am Acad Dermatol 43:691–697CrossRefPubMed
2.
Horio T, Imamura S, Danno K, Ofuji S (1981) Potassium iodide in the treatment of erythema nodosum and nodular vasculitis. Arch Dermatol 117:29–31PubMed
3.
Torinuki W (1994) Wegener's granulomatosis successfully treated with prednisolone and potassium iodide. J Dermatol 21:693–695PubMed
4.
Giessel M, Graves K, Kalivas J (1979) Treatment of disseminated granuloma annulare with potassium iodide. Arch Dermatol 115:639–640
5.
Klein KL, Pittelkow MR (1992) Tissue plasminogen activator for treatment of livedo vasculitis. Mayo Clinic Proc 67:923–933
6.
7.
Gibson LE, Su WPD (1995) Cutaneous vasculitis. Rheum Dis Clin North Am 21:1097–1113PubMed
8.
Yamamoto M, Danno K, Shio H, Imamura S (1988) Antithrombic treatment in livedo vasculitis. J Am Acad Dermatol 18:57–62PubMed
9.
Horio T, Danno K, Okamoto H, Miyachi Y, Imamura S (1983) Potassium iodide in erythema nodosum and other erythematous dermatoses. J Am Acad Dermatol 9:77–81PubMed
10.
Schulz EJ, Whiting DA (1976) Treatment of erythema nodosum and nodular vasculitis with potassium iodide. Br J Dermatol 94:75–78PubMed
11.
Rostas A, Lowe D, Smout MS (1980) Erythema nodosum migrans in a young woman. Arch Dermatol 116:325–326PubMed
12.
Woeber KA (1991) Iodine and thyroid disease. Med Clin North Am 75:169–178PubMed
13.
Honma K, Saga K, Onodera H, Takahashi M (1990) Potassium iodide inhibits neutrophil chemotaxis. Acta Derm Veneral (Stockh) 70:247–249
Metadata
Title
Severe livedo vasculitis treated with potassium iodide
Authors
Zeev Abraham
Michael Rozenbaum
Elena Portnoy
Itzhak Rosner
Publication date
01-03-2003
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 2/2003
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-002-0275-y

Other articles of this Issue 2/2003

Rheumatology International 2/2003 Go to the issue

Original Article

Early rheumatoid arthritis patients: relationship of age

Original Article

Body composition, bone mineral density, and circulating leptin levels in postmenopausal Turkish women

Review Article

Pathologic thrombopoiesis of rheumatoid arthritis

Original Article

Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis

Original Article

The efficacy of lumbar traction in the management of patients with low back pain

Original Article

Predictors of bone mineral density and osteoporosis in patients attending a rheumatology outpatient clinic
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits